Research Topics
| Miljenko V PilepichSummaryAffiliation: University of California Country: USA Publications
| Collaborators
|
Detail Information
Publications
Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31Miljenko V Pilepich
University of California, Los Angeles, School of Medicine, Los Angeles, CA, USA
Int J Radiat Oncol Biol Phys 61:1285-90. 2005..Radiation Therapy Oncology Group protocol 85-31 was designed to evaluate the effectiveness of adjuvant androgen suppression, using goserelin, in unfavorable prognosis carcinoma of the prostate treated with definitive radiotherapy (RT)...- Phase III study of pentosanpolysulfate (PPS) in treatment of gastrointestinal tract sequelae of radiotherapyMiljenko V Pilepich
Department of Radiation Oncology, UCLA, Los Angeles, CA, USA
Am J Clin Oncol 29:132-7. 2006..To evaluate the effectiveness of pentosanpolysulfate (PPS) in the treatment of gastrointestinal tract sequelae of radiotherapy... - Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610Mack Roach
Department of Radiation Oncology, University of California San Francisco, 1600 Divisadero St, Suite H1031, San Francisco, CA 94143 1708, USA
J Clin Oncol 26:585-91. 2008..This report summarizes long-term follow-up results... - Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02Jason A Efstathiou
Department of Radiation Oncology, Massachusetts General Hospital, 100 Blossom Street, Boston, MA 02114, USA
Eur Urol 54:816-23. 2008.... - Diabetes and mortality in men with locally advanced prostate cancer: RTOG 92-02Matthew R Smith
Department of Radiation Oncology, Division of Hematology and Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
J Clin Oncol 26:4333-9. 2008..Diabetes is associated with lower risk of prostate cancer. Most men with diabetes are obese, and obesity is associated with greater prostate cancer mortality. Whether diabetes influences outcomes after prostate cancer diagnosis is unknown... - Older age predicts decreased metastasis and prostate cancer-specific death for men treated with radiation therapy: meta-analysis of radiation therapy oncology group trialsDaniel A Hamstra
Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan 48109 5010, USA
Int J Radiat Oncol Biol Phys 81:1293-301. 2011.... - Race and survival of men treated for prostate cancer on radiation therapy oncology group phase III randomized trialsMack Roach
Department of Radiation Oncology, University of California-San Francisco, 1600 Divisadero Street, San Francisco, CA 94143-1708, USA
J Urol 169:245-50. 2003..We noted no evidence that race has independent prognostic significance in patients treated for prostate cancer in Radiation Therapy Oncology Group prospective randomized trials... - Protein kinase A RI-alpha predicts for prostate cancer outcome: analysis of radiation therapy oncology group trial 86-10Li Yan Khor
Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 71:1309-15. 2008.... - Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31Colleen A Lawton
Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI 53226, USA
J Clin Oncol 23:800-7. 2005..To update the effect of immediate androgen suppression in conjunction with standard external-beam irradiation versus radiation alone on a group of histologically lymph node-positive patients with adenocarcinoma of the prostate... - Obesity and mortality in men with locally advanced prostate cancer: analysis of RTOG 85-31Jason A Efstathiou
Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
Cancer 110:2691-9. 2007..Whether BMI is associated with prostate cancer-specific mortality (PCSM) was investigated in a large randomized trial of men treated with RT and androgen deprivation therapy (ADT) for locally advanced prostate cancer... - Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: promising long-term results of the Radiation Therapy Oncology Group--RTOG 9705Jeffrey D Bradley
Department of Radiation Oncology, Washington University Medical Center, 4921 Parkview Place LL, Mail Stop 90 38 635, St Louis, MO 63110, USA
J Clin Oncol 23:3480-7. 2005.... - Bcl-2 and bax expression and prostate cancer outcome in men treated with radiotherapy in Radiation Therapy Oncology Group protocol 86-10Li-Yan Khor
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 66:25-30. 2006..The cohort examined was comprised of patients with locally advanced disease and it is possible that these markers may be of greater value in men with earlier-stage prostate cancer... - Phase III double-blind study of glutamine versus placebo for the prevention of acute diarrhea in patients receiving pelvic radiation therapyTimothy F Kozelsky
Mayo Clinic, 200 First St, SW, Rochester, MN 55905, USA
J Clin Oncol 21:1669-74. 2003..99). The maximum number of stools per day was 5.1 for the glutamine arm and 5.2 for the placebo arm (P =.99). CONCLUSION: There is no evidence of a beneficial effect of glutamine during pelvic RT... - Overview of bladder cancer trials in the Radiation Therapy Oncology GroupWilliam U Shipley
Genitourinary Oncology Committee, Radiation Therapy Oncology Group, American College of Radiology, Philadelphia, Pennsylvania, USA
Cancer 97:2115-9. 2003....